Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene ...

PDUFA Goal date is November 16, 2024Company on track to submit a marketing authorization application to the European Medicines Agency (EMA) in the first half of 2024

Related Keywords

London ,City Of ,United Kingdom ,United States ,American ,Susana Noonan ,Lauren Williams ,Julia Wilson ,Olivia Manser ,Drug Administration ,Sa Noonan Communications ,Exchange Commission ,Nasdaq ,American Society Of Clinical Oncology ,European Medicines Agency ,Exchange Commission On ,Biologics License Application ,Adultb Cell Acute Lymphoblastic Leukemia ,Prescription Drug User Fee Act ,Pivotal Phase ,Clinical Oncology ,Annual Meeting ,American Society ,Hematology Meeting ,Christian Itin ,Chief Executive Officer ,Marketing Authorization Application ,Orphan Drug Designation ,Orphan Medical Product Designation ,Regenerative Medicine Advanced Therapy ,Autolus Therapeutics ,Private Securities Litigation Reform Act ,Autolu Annual Report ,Region ,